258 related articles for article (PubMed ID: 28537941)
1. Pathophysiology of ANCA-associated Vasculitis.
Al-Hussain T; Hussein MH; Conca W; Al Mana H; Akhtar M
Adv Anat Pathol; 2017 Jul; 24(4):226-234. PubMed ID: 28537941
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Harper L; Cockwell P; Adu D; Savage CO
Kidney Int; 2001 May; 59(5):1729-38. PubMed ID: 11318943
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of ANCA-Associated Pulmonary Vasculitis.
Alba MA; Jennette JC; Falk RJ
Semin Respir Crit Care Med; 2018 Aug; 39(4):413-424. PubMed ID: 30404109
[TBL] [Abstract][Full Text] [Related]
4. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update.
Gómez-Puerta JA; Bosch X
Am J Pathol; 2009 Nov; 175(5):1790-8. PubMed ID: 19815703
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis.
Marzano AV; Raimondo MG; Berti E; Meroni PL; Ingegnoli F
Clin Rev Allergy Immunol; 2017 Dec; 53(3):428-438. PubMed ID: 28578472
[TBL] [Abstract][Full Text] [Related]
6. New advances in the pathogenesis of ANCA-associated vasculitides.
Chen M; Kallenberg CG
Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S108-14. PubMed ID: 19646356
[TBL] [Abstract][Full Text] [Related]
7. [Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitides].
Kaliterna DM; Marinović I; Salamunić I
Reumatizam; 2013; 60(2):43-6. PubMed ID: 24979996
[TBL] [Abstract][Full Text] [Related]
8. [A preliminary study of the significance of autoantibodies against light chain of myeloperoxidase on pulmonary damages in myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
Zhang L; Shuai Z; Hu Z; Zhang M; Chen S
Zhonghua Nei Ke Za Zhi; 2015 Jun; 54(6):511-6. PubMed ID: 26359012
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation.
Ohlsson S; Holm L; Hansson C; Ohlsson SM; Gunnarsson L; Pettersson Å; Skattum L
PLoS One; 2019; 14(6):e0218272. PubMed ID: 31216309
[TBL] [Abstract][Full Text] [Related]
10. Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
Postgrad Med J; 2014 May; 90(1063):290-6. PubMed ID: 24737903
[TBL] [Abstract][Full Text] [Related]
11. Clinical analysis of patients with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis.
Shuai ZW; Lv YF; Zhang MM; Hu ZY
Genet Mol Res; 2015 May; 14(2):5296-303. PubMed ID: 26125725
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
Am J Kidney Dis; 2013 Dec; 62(6):1176-87. PubMed ID: 23810690
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of ANCA-associated vasculitis.
Lenka B; Zdenka H; Eva H
Cesk Patol; 2020; 56(2):65-67. PubMed ID: 32493021
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis.
Ueda Y; Nakazawa D; Nishio S; Shiratori-Aso S; Kudo T; Miyoshi-Harashima A; Watanabe-Kusunoki K; Hattanda F; Iwasaki S; Tsuji T; Tomaru U; Aratani Y; Yamamoto M; Ishizu A; Atsumi T
Kidney Int; 2024 Jun; 105(6):1291-1305. PubMed ID: 38537677
[TBL] [Abstract][Full Text] [Related]
15. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis.
Reynolds WF; Stegeman CA; Tervaert JW
Clin Immunol; 2002 May; 103(2):154-60. PubMed ID: 12027420
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides.
Kallenberg CG; Heeringa P; Stegeman CA
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):661-70. PubMed ID: 17133251
[TBL] [Abstract][Full Text] [Related]
17. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
Harper L; Radford D; Plant T; Drayson M; Adu D; Savage CO
Arthritis Rheum; 2001 Apr; 44(4):921-30. PubMed ID: 11315931
[TBL] [Abstract][Full Text] [Related]
18. Antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis after immunisation with bacterial proteins.
Savige J; Nassis L; Cooper T; Paspaliaris B; Martinello P; MacGregor D
Clin Exp Rheumatol; 2002; 20(6):783-9. PubMed ID: 12508769
[TBL] [Abstract][Full Text] [Related]
19. ANCA-associated vasculitis with renal involvement.
Binda V; Moroni G; Messa P
J Nephrol; 2018 Apr; 31(2):197-208. PubMed ID: 28560688
[TBL] [Abstract][Full Text] [Related]
20. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
Ann Rheum Dis; 2013 Aug; 72(8):1273-9. PubMed ID: 23606701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
